Evidence map›Paper›PMID 40907793›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2025

Polymer-based chemo-immunotherapy: Combining immunogenic cell death induction and PD-L1 blockade enhances antitumor immunity in melanoma.

Jiahui Li, Hasan Al Faruque, Emilio Cortes-Sanchez, Matthew VanBrocklin, Siwen Hu-Lieskovan, Morgan Cina, Arabella Young, Jindřich Kopeček, Jiyuan Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jiahui LiCenter for Controlled Chemical Delivery, University of Utah, Salt Lake City, UT 84112, USA; Department of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT 84112, USA.
Hasan Al FaruqueCenter for Controlled Chemical Delivery, University of Utah, Salt Lake City, UT 84112, USA; Department of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT 84112, USA.
Emilio Cortes-SanchezHuntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
Matthew VanBrocklinHuntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
Siwen Hu-LieskovanHuntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
Morgan CinaHuntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
Arabella YoungHuntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA; Department of Pathology, University of Utah, Salt Lake City, UT 84112, USA.
Jindřich KopečekCenter for Controlled Chemical Delivery, University of Utah, Salt Lake City, UT 84112, USA; Department of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT 84112, USA; Department of Biomedical Engineering, University of Utah, Salt Lake City, UT 84112, USA.
Jiyuan YangCenter for Controlled Chemical Delivery, University of Utah, Salt Lake City, UT 84112, USA; Department of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT 84112, USA. Electronic address: jiyuan.yang@utah.edu.

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6M
Developing strategies to inhibit cancer immunotherapy-induced immune-related adverse events without impeding anti-tumor immunityR00CA246061 · NCI · UNIVERSITY OF UTAH · PI YOUNG, ARABELLA · 2022 to 2024
$747k
NCI NIH HHS P30 CA042014NCI NIH HHS R00 CA246061
6 · The paper itself

Abstract

Melanoma remains a challenging malignancy despite the significant outcomes achieved with immune checkpoint inhibitor (ICI) monotherapy. Here, we investigated a polymer-based chemo-immunotherapy strategy combining KT-1, a backbone-degradable N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-epirubicin conjugate that induces immunogenic cell death (ICD), with MPPA, a multivalent HPMA copolymer-peptide antagonist of PD-L1 (PPA: (NYSKPTDRQYHF). In B16F10 melanoma, a 3-day dosing schedule significantly outperformed 7-day dosing. KT-1 monotherapy induced CD8

Indexed as

B7-H1 AntigenImmune Checkpoint InhibitorsMelanomaMelanoma, ExperimentalPolymersAcrylamidesAnimalsCD8-Positive T-LymphocytesCell Line, TumorFemaleImmunogenic Cell DeathImmunotherapyMiceMice, Inbred C57BLAcrylamidesB7-H1 AntigenCd274 protein, mouseImmune Checkpoint InhibitorsPolymersB16F10Backbone degradable HPMA copolymer conjugatesChemo-immunotherapyImmune checkpoint inhibitorMelanoma treatmentSingle-cell RNA sequencing

Identifiers

PMID40907793
PMCPMC12959252

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.